Inactive

The National Cancer Institute (NCI), Center for Cancer Research (CCR), Vaccine Branch (VB) requires CellGenix GMP rh IL-4 reagent for cancer vaccine clinical trials. The North American Industry Classi... The National Cancer Institute (NCI), Center for Cancer Research (CCR), Vaccine Branch (VB) requires CellGenix GMP rh IL-4 reagent for cancer vaccine clinical trials. The North American Industry Classification System code is 325414 – Biological Product (except Diagnostic) Manufacturing. This notice is NOT a request for competitive quotation. This is an unrestricted Sources Sought Notice (SSN)/Request for Information (RFI) and is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Cancer Institute (NCI). The purpose of this Sources Sought Notice is to identify qualified business concerns, especially small businesses, that are interested and capable of performing the work described herein, as well as obtain market information for planning purposes. Information received will be considered solely for the purpose of determining the appropriate acquisition method, including whether a set-aside is possible. Any interested party that believes it can meet the requirement, may submit a capability statement which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI to determine if the party can perform the requirement. Responses must be received no later than 12:00PM EST, September 21, 2022. All responses must be in writing and emailed to Lena Lee, Contract Specialist, via electronic mail at lena.lee@nih.gov. No collect calls will be accepted. Reference: 75N91022Q00169 on all correspondence. PLEASE SEE ATTACHED STATEMENT OF NEED